Loading…
Loading…
See exactly how NBDS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NBDS and 80,000+ other tickers.
Investing in companies we believe help create transformative change in their industries
Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Equities research analysts at B. Riley dropped their Q2 2024 earnings per share estimates for Cytosorbents in a research note issued on Wednesday, May 15th. B. Riley analyst Y. Zhi now forecasts that the medical research company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.35) per share. B. Riley also issued estimates for Cytosorbents’ Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.34) EPS and FY2025 earnings at ($0.28) EPS. Cytosorbents (NASDAQ:CTSO – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The firm had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. During the same quarter last year, the business posted ($0.17) earnings per share. CTSO has been the subject of a number of other reports. StockNews.com initiated coverage on Cytosorbents in a report on Saturday. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Tuesday, May 7th. Get Our Latest Research Report on CTSO Cytosorbents Stock Performance Shares of Cytosorbents stock opened at $0.97 on Monday. Cytosorbents has a one year low of $0.78 and a one year high of $4.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49. The company has a market cap of $52.55 million, a price-to-earnings ratio of -1.64 and a beta of 0.62. The business’s 50 day moving average price is $0.89 and its 200 day moving average price is $1.07. Institutional Trading of Cytosorbents Several hedge funds have recently made changes to their positions in the business. Key Client Fiduciary Advisors LLC boosted its stake in shares of Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares during the period. Raymond James & Associates purchased a new position in Cytosorbents in the fourth quarter worth approximately $56,000. Sargent Investment Group LLC lifted its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Avenir Corp lifted its stake in Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock. About Cytosorbents (Get Free Report) Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Neuberger Berman, a private, independent, employee-owned investment manager, is pleased to announce the completion of the conversion of two actively managed mutual funds to ETFs: Neuberger Berman China Equity ETF ("China ETF" - NYSE: NBCE) and Neuberger Berman Global Real Estate ETF ("Real Estate ETF" - NYSE: NBGR). Neuberger Berman believes ETFs can deliver the firm's investment expertise to a potentially wider range of investors.
While bonds have been the hottest ETF asset class in 2023, for the broader investment community, this is the year of AI investing. Just as many people no longer spell out “exchange traded funds” for ETFs, AI has become shorthand for artificial intelligence.
The question of how to capture the growth within the disruptive technology sector is becoming more pronounced as the Nasdaq 100 matures as an index. Neuberger Berman hopes to answer this question through its Neuberger Berman Disrupters ETF (NBDS).
While the ARK Innovation Fund (ARKK) continues to be popular among investors, Cathie Wood's flagship fund is down 78% from its February 2021 peak. The issues with ARKK have been well documented.